Omeros Corp (OMER)
4.21
-0.32
(-7.06%)
USD |
NASDAQ |
Mar 30, 12:55
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 264.51M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -28.66% |
| Valuation | |
| PE Ratio | 5.613 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 3.087 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 93.44% |
News
Headline
Wire
Time (ET)
Yahoo
03/29 09:07
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/10/2023* | 16:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/10/2023* | -- | Results | Q1 2023 | -- | -0.57 | -- | |
| 03/13/2023 | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 03/13/2023 | -- | Results | Q4 2022 | -0.73 | -0.59 | -24.05% | |
| 11/09/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/09/2022 | -- | Results | Q3 2022 | -0.87 | -0.58 | -49.14% | |
| 08/09/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/09/2022 | -- | Results | Q2 2022 | -0.66 | -0.66 | -0.51% |
*Estimated Date/Time
Earnings
Profile
| Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
| URL | https://www.omeros.com |
| Investor Relations URL | https://investor.omeros.com/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Mar. 13, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 29, 2023.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 163.39M |
| Net Income (TTM) | 47.42M |
| Total Assets (Quarterly) | 590.97M |
| Total Liabilities (Quarterly) | 505.28M |
| Shareholders Equity (Quarterly) | 85.68M |
| Cash from Operations (TTM) | -86.48M |
| Cash from Investing (TTM) | -127.56M |
| Cash from Financing (TTM) | 124.25M |
Ratings
Profile
| Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
| URL | https://www.omeros.com |
| Investor Relations URL | https://investor.omeros.com/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Mar. 13, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| QQQS | 29224.00 USD | 0.61% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| OMER Tweets |